Copd Wire
Comprehensive News Feed for Copd.
Results 1 - 20 of 122 in Copd
-
... s approval of Spiriva HandiHaler (tiotropium bromide). The inhaler is already approved as a maintenance treatment for COPD, which includes chronic bronchitis and emphysema. a oeExacerbations of COPD are serious events that can negatively impact the ... Comment?
-
FDA Approves Spiriva HandiHaler for the Reduction of COPD Exacerbations
... bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). Spiriva HandiHaler is already FDA-approved as a once-daily maintenance treatment for breathing problems associated with ... Comment?
-
... s approval of Spiriva HandiHaler (tiotropium bromide). The inhaler is already approved as a maintenance treatment for COPD, which includes chronic bronchitis and emphysema. a oeExacerbations of COPD are serious events that can negatively impact the ... Comment?
-
Spiriva Inhaler Approved To Reduce Flares of COPD
... bromide inhalation powder) to include reducing symptoms during flares of chronic obstructive pulmonary disease (COPD), makers Boehringer Ingleheim Pharmaceuticals and Pfizer said. COPD is a broad term for respiratory disorders that include chronic ... Comment?
-
Symptoms of chronic obstructive pulmonary disease (COPD) in smokers include chronic cough, shortness of breath, and frequent respiratory infections. In patients with emphysema shortness of breath is the primary symptom. In patients with bronchitis ... Comment?
-
FDA Approves Boehringer Ingelheim Corporation and Pfizer Inc.'s...
... bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). SPIRIVA HandiHaler is already FDA-approved as a once-daily maintenance treatment for breathing problems associated with ... Comment?
-
... and Susie Sargent; a brother, J. Robert Maguire; and 16 grandchildren. In lieu of flowers, donations may be made to the COPD Foundation, 2937 Southwest 27th St., Suite 302, Miami, Fla., 33133. A Memorial Mass for former township resident Jane M. ... Comment?
-
Almirall and Forest Laboratories to Expand Respiratory Collaboration with LAS100977
... Almirall's proprietary GENUAIR inhaler for the treatment of both asthma and Chronic Obstructive Pulmonary Disease (COPD). Under the terms of the agreement, Forest will make an upfront payment to Almirall of $75 million and will pay future, ... Comment?
-
New genes for lung disease discovered
... The new findings provide hope for better treatment for lung diseases like Chronic Obstructive Pulmonary Disease (COPD) and asthma. In the past it has been difficult to develop new treatments because the molecular pathways that affect the health of ... Comment?
-
New genetic variants for COPD discovered in a groundbreaking study by SpiroMeta Consortium
... The new findings provide hope for better treatment for lung diseases like Chronic Obstructive Pulmonary Disease (COPD) and asthma. In the past it has been difficult to develop new treatments because the molecular pathways that affect the health of ... Comment?
-
New genes for lung disease discovered
... The new findings provide hope for better treatment for lung diseases like Chronic Obstructive Pulmonary Disease (COPD) and asthma. In the past it has been difficult to develop new treatments because the molecular pathways that affect the health of ... Comment?
-
... bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). "Onbrez Breezhaler has demonstrated greater improvements in lung function, breathlessness and quality of life compared to current ... Comment?
-
Novartis Receives Approval In The European Union For OnbrezA ...
... bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). "Onbrez Breezhaler has demonstrated greater improvements in lung function, breathlessness and quality of life compared to current ... Comment?
-
Filed under: in the news... When you browse as many headlines and press releases as we do, you can tell when someone is trying hard to grab your attention: Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment: Laser -type device to be coupled with Stem Cell Therapy in Novel ... Comment?
-
re: Does having Allergies cause Copd?
The leading cause of COPD is smoking the primary cause, however, the statement that allergies do not cause COPD is not only false but very nieve , who ever wrote this statement needs to re-educate themselves!! Monday, November 23, 2009 d bengal Allergies can contribute to the development and symptoms of COPD, but are typically not the only ... Comment?
-
Theravance, Inc.: Wait to Buy on Dip
... also predicted "an initial slow sales ramp of VIBATIV". But what is really interesting for THRX is the next generation COPD program, in collabration with GSK . This is a potential blockbuster drug, and the phase II data so far has been very ... Comment?
-
Entest Biomedical Enters into Discussions with Laser Manufacturer to...
- Entest Biomedical, Inc. (OTCBB: ENTB) announced that it has initiated discussions with a manufacturer of lasers regarding the development of a proprietary laser device which shall be owned by Entest and used in conjunction with several stem cell therapies currently being developed by Entest. These therapies are aimed at increasing efficacy in treating Chronic Obstructive Pulmonary Disease (COPD). A spokesman for Entest stated that this particular manufacturer was approached due to their success in commercializing medical devices in the North American market. "Biotechnology R&D companies like Entest frequently have intellectual property tied to medical devices under development. Entest's planned usage of laser-type devices in treating COPD requires the adaptation of current laser technology into a device that supports the Company's Stem Cell / Photoceutical therapy." said David Koos, Chairman and CEO of Entest. "Companies such as PhotoThera in Carlsbad, California, have successfully used this approach in developing their laser-based NeurotheraO technology for treating ischemic stroke patients (currently in Phase III clinical trials)." Entest's patent-pending approach revolves around the use of the patient's own stem cells in combination with specific laser wavelengths to repair damaged lung tissue of patients with COPD. Ernest's goal is the generation of schematics, code, and intellectual property pertaining to the new device which will serve as the basis for regulatory filings and FDA development of the Entest "regenerative photoceutical" approach to COPD. About Entest BioMedical Inc.: Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). Disclaimer This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. Contact: David R. Koos, Chairman & CEO 619.702.1404 Direct 619.330.2328 Fax Entest BioMedical Inc. www.EntestBio.com ### Media Contact: Entest BioMedical Inc. David Koos 619.702.1404 Trackback URL: Comment?
-
Entest Biomedical Enters into Discussions with Laser Manufacturer to...
- Entest Biomedical, Inc. (OTCBB: ENTB) announced that it has initiated discussions with a manufacturer of lasers regarding the development of a proprietary laser device which shall be owned by Entest and used in conjunction with several stem cell therapies currently being developed by Entest. These therapies are aimed at increasing efficacy in treating Chronic Obstructive Pulmonary Disease (COPD). A spokesman for Entest stated that this particular manufacturer was approached due to their success in commercializing medical devices in the North American market. "Biotechnology R&D companies like Entest frequently have intellectual property tied to medical devices under development. Entest's planned usage of laser-type devices in treating COPD requires the adaptation of current laser technology into a device that supports the Company's Stem Cell / Photoceutical therapy." said David Koos, Chairman and CEO of Entest. "Companies such as PhotoThera in Carlsbad, California, have successfully used this approach in developing their laser-based NeurotheraO technology for treating ischemic stroke patients (currently in Phase III clinical trials)." Entest's patent-pending approach revolves around the use of the patient's own stem cells in combination with specific laser wavelengths to repair damaged lung tissue of patients with COPD. Ernest's goal is the generation of schematics, code, and intellectual property pertaining to the new device which will serve as the basis for regulatory filings and FDA development of the Entest "regenerative photoceutical" approach to COPD. About Entest BioMedical Inc.: Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). Disclaimer This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. Contact: David R. Koos, Chairman & CEO 619.702.1404 Direct 619.330.2328 Fax Entest BioMedical Inc. www.EntestBio.com ### Media Contact: Entest BioMedical Inc. David Koos 619.702.1404 Trackback URL: Comment?
-
... Boehringer Ingelheim that the Spiriva HandiHaler (tiotropium bromide) reduces worsening of symptoms in patients with COPD. The two companies are seeking approval for the use of the drug, in addition to its already approved use as a maintenance ... Comment?
-
Thousands in Bolton suffer from crippling illness
... without knowing. Health experts believe up to 10,000 people could have condition chronic obstructive pulmonary disease (COPD), But only 4,000 in Bolton are registered as sufferers. Now the Royal Bolton Hospital has spoken out to raise awareness of ... Comment?
Copd Forum
Most Popular
- U.S. Democrats secure 60th vote on health bill - 358 comments
- DC Mom Files Complaint Against Lesbian Teacher for Corrupting Child's Innocence - 159 comments
- Aide quits Paul's Senate campaign after blog post - 211 comments
- The 3 Michigan Churches Who Are Quitting the Homeless Because Another Church ... - 146 comments
- Zizie Ezette & Bung Mokhtar Dikatakan Berkahwin Tapi Bung Nafi - 106 comments
- 1 Year Later-Obama's Legacy of Lies and Broken Promises - 94 comments
- Evangelical church opens doors fully to gays ... - 139 comments
- Workers strike at Barbourville manufacturer - 69 comments
- HERE WE GO AGAIN, CLOSE THE BOGIE DOWN? FIGHTS AND STABBINGS AGAIN - 38 comments
- Exclusive: Nelson Explains Stance On Health Care - 68 comments
|
Reach local customers. Engage a specific demographic. Maximize business-to-business opportunities. Topix can deliver your message.
|
Copyright ©2009 Topix LLC
